- Trials with a EudraCT protocol (42)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
42 result(s) found for: Vineland Adaptive Behavior Scale.
Displaying page 1 of 3.
EudraCT Number: 2020-003173-22 | Sponsor Protocol Number: BP30153 | Start Date*: 2020-11-12 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: A Phase II Multi-Center, Randomized, Double-Blind, 24-Week, Parallel Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Children and Adolescents Age... | ||
Medical condition: Autism Spectrum Disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2013-003259-39 | Sponsor Protocol Number: NeuroClin02 | Start Date*: 2014-03-28 |
Sponsor Name:Neurochlore | ||
Full Title: A Phase II dose ranging study of Bumetanide solution in children and adolescents with autism spectrum disorders. | ||
Medical condition: Diseases and Related Health Problems, tenth revision (ICD-10) and with a Childhood Autism Rating Scale (CARS) score > 34. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003904-21 | Sponsor Protocol Number: ABT-001 | Start Date*: 2016-08-01 |
Sponsor Name:Abeona Therapeutics Inc | ||
Full Title: Phase I/II gene transfer clinical trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA | ||
Medical condition: MPS IIIA is a devastating lysosomal storage disease, caused by a N-sulfoglucosamine sulfohydrolase gene defect. Infants with MPS IIIA appear normal at birth, but the disease is relentlessly progres... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001834-27 | Sponsor Protocol Number: GWEP1415 | Start Date*: 2015-01-14 | |||||||||||
Sponsor Name:GW Research Ltd | |||||||||||||
Full Title: An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes | |||||||||||||
Medical condition: Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) PL (Completed) NL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004949-92 | Sponsor Protocol Number: E2020-A001-336 | Start Date*: 2017-03-09 |
Sponsor Name:Eisai Inc. | ||
Full Title: A 10-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride (Aricept) in the Treatment of the Cognitive Dysfunction Exhibited by Children with... | ||
Medical condition: Down Syndrome, Cognitive Dysfunction | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-000504-42 | Sponsor Protocol Number: ABT-003 | Start Date*: 2019-05-21 | |||||||||||
Sponsor Name:Abeona Therapeutics Inc | |||||||||||||
Full Title: A Phase I/II Open Label, Single-dose, Gene Transfer Study of scAAV9.U1a.hSGSH (ABO-102) in Patients with Middle and Advanced Phases of MPS IIIA Disease | |||||||||||||
Medical condition: MPS IIIA is a devastating lysosomal storage disease, caused by a Nsulfoglucosamine sulfohydrolase gene defect. Infants with MPS IIIA appear normal at birth, but the disease is relentlessly progress... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001411-39 | Sponsor Protocol Number: ABT-002 | Start Date*: 2018-09-04 |
Sponsor Name:Abeona Therapeutics Inc | ||
Full Title: Phase I/II gene transfer clinical trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB | ||
Medical condition: MPS IIIB is a devastating lysosomal storage disease, caused by a N-α-acetylglucosaminidase (NAGLU) gene defect. Infants with MPS IIIB appear normal at birth, but the disease is relentlessly progre... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004804-31 | Sponsor Protocol Number: SHP-ELA-401 | Start Date*: 2016-04-12 |
Sponsor Name:Shire Human Genetic Therapies, Inc. (Shire), a wholly owned subsidiary of Takeda Pharmaceutical Company Limited | ||
Full Title: A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients with MPS II Who Are Receiving Elaprase and Started Treatment With Elaprase at <6... | ||
Medical condition: Hunter syndrome (Mucopolysaccharidosis II, [MPS II]) | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002979-34 | Sponsor Protocol Number: LTFU-ABO-102 | Start Date*: 2020-05-18 | |||||||||||
Sponsor Name:Abeona Therapeutics Inc | |||||||||||||
Full Title: A Long-term Follow-up Study of Patients with MPS IIIA from Gene Therapy Clinical Trials Involving the Administration of ABO-102 (scAAV9.U1a.hSGSH) | |||||||||||||
Medical condition: MPS IIIA is a devastating lysosomal storage disease, caused by a Nsulfoglucosamine sulfohydrolase gene defect. Infants with MPS IIIA appear normal at birth, but the disease is relentlessly progress... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004349-42 | Sponsor Protocol Number: NP27936 | Start Date*: 2012-07-16 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A randomized, double-blind, 12- week, parallel group, placebo-controlled study of the efficacy and safety of RO4917523 in patients with Fragile X Syndrome. | |||||||||||||
Medical condition: Fragile X Syndrome (FXS) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) ES (Completed) | |||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2014-002940-42 | Sponsor Protocol Number: GWEP1414 | Start Date*: 2015-07-28 | |||||||||||
Sponsor Name:GW Research Ltd | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P; CBD) as adjunctive treatment for seizures associated with Lennox-Gastaut synd... | |||||||||||||
Medical condition: Lennox-Gastaut syndrome (LGS) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002941-23 | Sponsor Protocol Number: GWEP1423 | Start Date*: 2015-09-30 | |||||||||||
Sponsor Name:GW Research Ltd. | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P; CBD) as adjunctive treatment for seizures associated with Lennox- Gastaut syn... | |||||||||||||
Medical condition: Lennox-Gastaut syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002154-67 | Sponsor Protocol Number: A-MANECE-2013 | Start Date*: 2013-12-26 | |||||||||||
Sponsor Name:Dra. Cristina Avendaño Solá | |||||||||||||
Full Title: RANDOMIZED CLINICAL TRIAL, PLACEBO COMPARED TO EVALUATE THE EFFICACY AND SAFETY OF MINOCYCLINE IN ANGELMAN SYNDROME (A-MANECE STUDY) | |||||||||||||
Medical condition: Angelman Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000178-20 | Sponsor Protocol Number: MCT8-2014-1 | Start Date*: 2015-08-12 |
Sponsor Name:Erasmus Medical Centre | ||
Full Title: Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. | ||
Medical condition: This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic ... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male | |
Trial protocol: BE (Completed) CZ (Completed) DE (Completed) IT (Completed) FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000942-21 | Sponsor Protocol Number: AIMS-2-CT1 | Start Date*: 2019-07-24 | |||||||||||||||||||||
Sponsor Name:Celso Arango | |||||||||||||||||||||||
Full Title: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents w... | |||||||||||||||||||||||
Medical condition: Autism Spectrum Disorder | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000195-15 | Sponsor Protocol Number: P4-SAF-302 | Start Date*: 2018-12-27 | |||||||||||
Sponsor Name:Lysogene SA | |||||||||||||
Full Title: An Open-Label, Single-Arm, Multicenter Study of Intracerebral Administration of Adeno-Associated Viral Vectors Serotype rh10 Carrying the Human N-sulfoglucosamine sulfohydrolase (SGSH) cDNA for the... | |||||||||||||
Medical condition: Mucopolysaccharidosis Type IIIA | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) NL (Temporarily Halted) DE (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003791-13 | Sponsor Protocol Number: BP42992 | Start Date*: 2022-01-11 | |||||||||||
Sponsor Name:F. HOFFMANN - LA ROCHE LTD. | |||||||||||||
Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACODYNAMICS OF 52 WEEKS OF TREATMENT WITH BASMISANIL IN CHILDREN WITH DUP15... | |||||||||||||
Medical condition: Dup15q Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) PL (Completed) NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002485-39 | Sponsor Protocol Number: TAK-935-18-001(OV935)Amendment1 | Start Date*: 2019-06-14 |
Sponsor Name:Ovid Therapeutics, Inc. | ||
Full Title: A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEP... | ||
Medical condition: developmental and epileptic encephalopathies | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) PL (Trial now transitioned) PT (Trial now transitioned) Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2021-005200-35 | Sponsor Protocol Number: DNLI-E-0007 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Denali Therapeutics Inc. | |||||||||||||
Full Title: A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Tividenofusp (DNL310) vs Idursulfase in Pediatric and Young Adults Participants With Neuronopathic ... | |||||||||||||
Medical condition: Mucopolysaccharidosis Type II [MPS II] | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) NL (Ongoing) ES (Ongoing) BE (Ongoing) FR (Trial now transitioned) CZ (Trial now transitioned) SE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005241-31 | Sponsor Protocol Number: IEDAT-02-2015 | Start Date*: 2016-09-14 | |||||||||||
Sponsor Name:EryDel S.p.A. | |||||||||||||
Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients with Ataxia Telan... | |||||||||||||
Medical condition: Patient with neurological symptoms of Ataxia Telangiectasia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) NO (Completed) ES (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
